

IBL HEALTHCARE LIMITED
CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-audited)
FOR THE PERIOD ENDED MARCH 31, 2024

	Note	Quarter ended		Nine-months ended	
		March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023
------(Rs. in '000)-----					
Revenue from contract with customers	12	1,103,244	985,087	3,181,942	3,010,903
Cost of Sales		(684,058)	(663,879)	(2,075,077)	(2,020,158)
Gross Profit		419,186	321,209	1,106,865	990,746
Other income / (loss)	13	6,078	62,765	32,917	14,901
Marketing and distribution expenses		(304,494)	(189,758)	(734,047)	(485,320)
Administrative and general expenses		(24,371)	(23,739)	(77,298)	(72,799)
Finance cost	14	(15,594)	(19,003)	(53,940)	(50,017)
Profit before taxation		80,805	151,474	274,497	397,511
Income tax expense		(29,857)	(53,899)	(92,517)	(128,680)
Profit after taxation		50,948	97,576	181,980	268,832
Other comprehensive income		-	-	-	-
Total comprehensive income		50,948	97,576	181,980	268,832
			(Re-stated)		(Re-stated)
Earnings per share - basic and diluted		0.59	1.14	2.12	3.14

The annexed notes 1 to 16 form an integral part of this condensed interim financial statements.


Chief Executive Officer
Director
Chief Financial Officer